Question explored with the scientific record
Is prednosone safe?
Prednisone is a powerful drug that reliably suppresses the immune system and the adrenal glands. It is not "safe" in the way a vitamin is safe. Its safety depends entirely on dose, duration, and the person taking it.
The evidence here shows that prednisone's harms are real and dose-dependent. A large retrospective study of 37,891 asthmatics found that every 1,000 mg increase in cumulative prednisone raised the risk of osteoporosis, fractures, and cataracts by 2-3% [8]. In a randomized trial of 217 COPD patients in the ICU, prednisone at 1 mg/kg/day provided no benefit in mortality or ventilation time but did cause more severe hyperglycemia [6]. A case report of a 56-year-old man with immune thrombocytopenia on 80 mg daily of prednisone stopped the drug because of severe hyperglycemia, even though his platelet count had normalized [7]. In seven healthy men, just four days of 60 mg prednisone cut the growth hormone response to stimulation by 70% [3].
The mechanism is straightforward. Prednisone is a synthetic glucocorticoid. It shuts down the hypothalamic-pituitary-adrenal (HPA) axis. A 1979 study of 14 cancer patients found that short courses of high-dose prednisone suppressed adrenal function in most of them for at least 24 hours, with recovery taking up to 7 days [1]. Inhaled corticosteroids have much less systemic effect, but oral prednisone at 10 mg daily still markedly suppressed adrenal function in a 1999 trial [2]. The elderly are at higher risk because they clear the drug more slowly, leading to higher blood levels [5].
The benefit is real for specific conditions. In 106 hyperandrogenic women, prednisone at 7.5-10 mg daily suppressed testosterone by 42% and restored ovulation in 91% of anovulatory patients [4]. In Crohn's disease, steroid use was linked to spine bone loss over time, but the disease itself also causes bone loss [9]. The trade-off is always present.
My call: prednisone is a necessary tool for serious inflammatory and autoimmune conditions, but it is never a safe drug. The evidence shows clear, dose-dependent harms to bone, glucose metabolism, growth hormone, and adrenal function. The burden of proof is on the prescriber to show that the benefit outweighs these known risks for the specific person and the specific duration. Confidence: high.
Sources used 9
-
ADRENAL SUPPRESSION AFTER SHORT-TERM CORTICOSTEROID THERAPY
In cancer patients receiving short-term high-dose prednisone as part of chemotherapy, adrenal function was suppressed in most individuals for at least 24 hours, with recovery variably delayed (up to 7 days) and not clearly related to dose or duration, highlighting potential subc…
DOI: 10.1016/s0140-6736(79)91077-8 -
Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma
Two multicenter randomized trials in adults with mild-to-moderate asthma found that inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide have similar minimal adverse effects on the hypothalamic-pituitary-adrenal axis to placebo, whereas oral p…
DOI: 10.1016/s0149-2918(00)88292-2 -
Inhibition by Prednisone of Growth Hormone (GH) Response to GH-Releasing Hormone in Normal Men
Prednisone suppresses the growth hormone (GH) response to GH-releasing hormone (GHRH) in seven normal men, indicating glucocorticoids inhibit GH secretion at or above the pituitary level (likely via hypothalamic mechanisms).
DOI: 10.1210/jcem-67-6-1258 -
Effect of Prednisone on Plasma Testosterone Levels and on Duration of Phases of the Menstrual Cycle in Hyperandrogenic Women
Prednisone therapy in hyperandrogenic women significantly suppressed plasma testosterone, initiated ovulatory activity in amenorrheic and anovulatory patients, and shortened follicular phase while lengthening luteal phase in ovulatory women.
DOI: 10.1016/s0015-0282(16)44296-2 -
Kinetics of prednisolone and endogenous cortisol suppression in the elderly
In elderly humans, prednisolone exposure after prednisone or prednisolone is higher due to reduced metabolic and renal clearance, yet cortisol suppression is attenuated, indicating age-related pharmacokinetic and pharmacodynamic changes.
DOI: 10.1038/clpt.1988.43 -
Systemic steroids in severe forms of COPD exacerbations: a question of balance?
An editorial assessing ABROUG et al.'s open-label randomized trial of prednisone in COPD patients with severe exacerbations requiring ICU ventilatory support, noting no ICU mortality or ventilation outcome benefit and highlighting higher hyperglycemia, thus arguing against routi…
DOI: 10.1183/09031936.00000214 -
Treatment of Immune Thrombocytopenia
A single-patient case report teaching primary-care management of immune thrombocytopenia (ITP): avoid unnecessary corticosteroids in asymptomatic patients with platelet counts above 30×10^9/L, illustrated by a 56-year-old man's transient bleeding improvement on prednisone and su…
DOI: 10.1001/jamainternmed.2017.7614 -
Oral Corticosteroid Use Increases the Risk of Glucocorticoid-related Adverse Events in Asthmatics
Greater cumulative exposure to oral corticosteroids in adults with asthma is associated with statistically significant increases in glucocorticoid-related adverse events—specifically osteoporosis, fractures, and cataracts—based on a large retrospective cohort of 37,891 asthmatic…
DOI: 10.1016/j.jaci.2011.12.600 -
Risk Factors for Low Bone Density in Crohn's Disease
Osteopenia and osteoporosis are highly prevalent in Crohn's disease and are associated with age, BMI, and lifetime steroid exposure; disease activity shows no clear association with BMD, and spine bone loss increases with ongoing steroid use over time.
DOI: 10.1097/00054725-200203000-00003